ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

Novartis: Pasireotide Works Well In Acromegaly Trial

By Marta Falconi Of DOW JONES NEWSWIRES ZURICH -(Dow Jones)- An experimental drug by Novartis (NVS) for the treatment of a rare endocrine disorder is working better than the standard of care in a late-stage clinical trial, the company said Monday. Patients treated with pasireotide LAR, or SOM230, were 63% more likely to achieve control of their disease than those treated with Novartis' Sandostatin LAR, or octreotide, the study showed. The safety profile of pasireotide LAR was similar to that of octreotide LAR, known under the brand name Sandostatin, with the exception of a higher degree of hyperglycemia, Novartis said. "The positive results seen in the Phase III trial point to the potential role of pasireotide LAR in treating patients with acromegaly, a condition for which there remains an unmet need," said Herve Hoppenot, president of Novartis Oncology, in a statement. "These findings are welcome news as we continue our research efforts to discover treatments for patients with pituitary-related conditions." Acromegaly, a rare endocrine disorder caused by excess growth hormone, can result in enlarged hands, feet and internal organs, and increased risk of death. Novartis said the data were presented at the 15th International Congress of Endocrinology and 14th European Congress of Endocrinology meeting in Florence, Italy. The medical meeting runs from May 5 to May 9. -By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; marta.falconi@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
04/25/201507:06:02Are Biosimilars the Next Big Thing in Biotech?
04/23/201518:21:48ADR Shares End Higher; Ericsson Drops, Logitech Rises
04/23/201512:49:55Eli Lilly Results Top Expectations
04/23/201512:44:52Eli Lilly Results Top Expectations
04/23/201512:32:22Novartis Begins to See Benefits of Overhaul -- 2nd Update
04/23/201506:59:03Novartis Begins to See Benefits of Overhaul -- Update
04/23/201503:58:06Novartis Profit Boosted by Disposals
04/23/201502:54:59Novartis Profit Boosted by Disposals
04/22/201519:20:35CSL Says CFO Naylor to Lead Influenza-Vaccine Business
04/22/201510:03:023 Soaring Biotech Stocks Under $10 -- Are They Buys?
04/20/201518:59:29Why Shares of Juno Therapeutics Inc. and Kite Pharma Inc. Crashed...
04/20/201517:43:06Novartis 1Q 2015 -- Forecast
04/19/201507:14:033 Megatrends in Healthcare
04/18/201509:19:03Meet the Game-Changing Drug Designed to Fight America's Leading...
04/16/201517:15:08Why Momenta Pharmaceuticals Inc. Shares Are Surging Higher
04/16/201516:51:37FDA Approves Generic Multiple-Sclerosis Drug by Novartis's Sandoz...
04/16/201516:07:15FDA Approves Novartis and Momenta's Generic Multiple-Sclerosis...
04/16/201508:58:023 Potential Blockbuster Drugs That Could Be Approved Before Year's...
04/15/201508:59:033 Biotech Stocks That May Disappear Before 2020
04/14/201508:44:32The Growing Business Of Animal Healthcare

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad